---

DIABETES IN PREGNANCY

A Comprehensive Postgraduate-Level Review

---

1. CLASSIFICATION

A. Pregestational Diabetes Mellitus (PGDM)

B. Gestational Diabetes Mellitus (GDM)

White Classification (Modified)

---

2. PATHOPHYSIOLOGY

Normal Pregnancy Metabolic Changes

• Early pregnancy (12-14 weeks): Mild increase in insulin sensitivity (paradoxical), accompanied by a markedly elevated Disposition Index (DI) suggesting profound beta-cell stimulation
• Late pregnancy (34-36 weeks): Profound insulin resistance (~50-60% decrease in insulin sensitivity from pregravid baseline), driven by placental anti-insulin hormones

• Human Placental Lactogen (hPL) - major driver
• Progesterone
• Cortisol
• Prolactin
• Placental Growth Hormone

GDM Pathophysiology

• Increased basal endogenous glucose production
• Decreased insulin-mediated suppression of hepatic glucose output (~80% vs 95% in controls)
• The degree of insulin resistance is similar to matched controls, but the beta-cell secretory response is inadequate - this is the core defect
• Pre-pregnancy insulin resistance (related to obesity, PCOS, adiposity) magnifies the gestational resistance

---

3. RISK FACTORS FOR GDM

---

4. SCREENING AND DIAGNOSIS

FLOWCHART 1: GDM Screening Algorithm

ALL PREGNANT WOMEN
        │
        ▼
EARLY PREGNANCY (<13 wks)
        │
        ├── HIGH RISK for PGDM?
        │   (Obesity, prior GDM, strong FH, glycosuria,
        │    hypertension, prior macrosomia)
        │           │
        │           ▼
        │   Screen using NON-PREGNANT criteria:
        │   - FBG ≥126 mg/dL → Overt DM
        │   - HbA1c ≥6.5% → Overt DM
        │   - Random glucose ≥200 mg/dL + symptoms → Overt DM
        │   - FBG 92-125 mg/dL → GDM
        │
        └── STANDARD RISK → Proceed to 24-28 weeks
                │
                ▼
        24-28 WEEKS GESTATION
        ┌─────────────────────────────┐
        │                             │
        ▼                             ▼
  TWO-STEP (ACOG)            ONE-STEP (IADPSG/WHO)
  50g GCT (fasting optional)    75g 2-hr OGTT (fasting)
        │
  ≥130 or ≥140 mg/dL at 1hr
        │
        ▼
  100g 3-hr OGTT (fasting)
  GDM = 2 values exceed thresholds

Diagnostic Criteria

Two-Step Method (ACOG - USA Standard):

• Administered fasting or non-fasting
• Threshold: ≥130 mg/dL (more sensitive) or ≥140 mg/dL (more specific)
• If positive → proceed to Step 2

One-Step Method (IADPSG/ADA/WHO):

---

5. MATERNAL COMPLICATIONS

A. Pregestational Diabetes

B. Retinopathy in Pregnancy

• Some form of retinopathy present in ~100% of T1DM women with disease >25 years
• Pregnancy-related progression predicted by: elevated prepregnancy HbA1c AND diabetes duration ≥10 years
• CSII (insulin pump) significantly decreases progression risk
• Postpartum regression rate: 9.3%; progression rate: 4.1%
• Laser photocoagulation effective for arresting progression
• Dilated fundal exam required: before pregnancy + first trimester + each trimester if disease present

C. Nephropathy in Pregnancy

• Normal: albumin/creatinine ratio <30 μg/mg
• Microalbuminuria: 30-299 μg/mg
• Macroalbuminuria (nephropathy): >300 μg/mg

D. Diabetic Ketoacidosis (DKA) in Pregnancy

• Occurs at lower glucose levels than in non-pregnant patients (~180 mg/dL threshold for screening during pregnancy)
• Pregnant women >20 weeks are more prone to severe and rapidly progressive episodes
• Most common in 2nd/3rd trimester and new-onset T1DM
• Triggers: infection, emesis, insulin non-compliance, steroid use, tocolytics (β-agonists)
• Associated with fetal distress and fetal loss

---

6. FETAL AND NEONATAL COMPLICATIONS

DIAGRAM: Pedersen Hypothesis (Hyperglycemia-Hyperinsulinism)

Maternal Hyperglycemia
        │
        ▼
Glucose crosses placenta freely
        │
        ▼
Fetal Hyperglycemia
        │
        ▼
Fetal Pancreatic Beta-cell Hyperplasia
        │
        ▼
Fetal Hyperinsulinism
        │
    ┌───┴────────────┐
    ▼                ▼
MACROSOMIA      Impaired surfactant
(anabolic effect  production → RDS
of insulin on
adipose/muscle)
    │
    ▼
Shoulder dystocia
Birth trauma
Brachial plexus injury

Summary of Fetal/Neonatal Complications

---

7. PRECONCEPTION COUNSELING AND MANAGEMENT

Goals of Preconception Care (PGDM)

1. HbA1c <6% before conception (ADA recommendation) to minimize congenital malformations
2. Switch to insulin (metformin and oral agents generally discontinued)
3. Assess and treat end-organ complications: retinopathy, nephropathy, neuropathy, cardiovascular disease
4. Optimize blood pressure control (stop ACE inhibitors/ARBs - teratogenic)
5. Folic acid supplementation: 5 mg/day (high-dose) - reduces NTD risk
6. Thyroid function assessment (especially T1DM - associated autoimmune thyroid disease)

---

8. ANTENATAL MANAGEMENT

FLOWCHART 2: Management Algorithm for Diabetes in Pregnancy

DIAGNOSIS OF GDM or PGDM
           │
           ▼
MULTIDISCIPLINARY TEAM
(Obstetrician + Endocrinologist + Dietitian + Diabetic Nurse Educator)
           │
           ▼
    INITIAL ASSESSMENT
    - HbA1c, FBG, renal function, urine ACR
    - Fundoscopy (PGDM)
    - Detailed anomaly scan (PGDM: at 18-20 wks)
    - Fetal echocardiography (PGDM: at 22-24 wks)
           │
           ▼
    LIFESTYLE MODIFICATION (ALL patients - first 1-2 weeks)
    - Medical Nutrition Therapy (MNT)
    - Moderate-intensity aerobic exercise (150 min/week)
    - Weight gain targets (IOM guidelines)
           │
      ┌────┴────┐
TARGETS MET?  TARGETS NOT MET?
      │              │
      ▼              ▼
Continue MNT   PHARMACOLOGICAL THERAPY
      │              │
      │        ┌─────┴──────┐
      │        ▼            ▼
      │    INSULIN       ORAL AGENTS
      │   (preferred)  (Metformin/Glyburide
      │                if insulin declined)
           │
           ▼
    BLOOD GLUCOSE MONITORING
    (Self-monitoring 4-7x/day: fasting + 1-hr or 2-hr post-meals)
           │
           ▼
    GLYCEMIC TARGETS (ADA):
    - Fasting: <95 mg/dL (5.3 mmol/L)
    - 1-hr postprandial: <140 mg/dL (7.8 mmol/L)
    - 2-hr postprandial: <120 mg/dL (6.7 mmol/L)
           │
           ▼
    FETAL SURVEILLANCE
    (See Section 9)
           │
           ▼
    DELIVERY PLANNING
    (See Section 10)

Medical Nutrition Therapy (MNT)

• Caloric distribution: 33-40% carbohydrates, 35-40% fat, 20-25% protein
• 3 meals + 2-3 snacks per day; breakfast carbohydrate intake should be minimal (insulin resistance is highest in the morning)
• Target weight gain: depends on pre-pregnancy BMI (IOM guidelines)
• Avoid simple sugars; prefer low-glycemic-index foods

Pharmacological Management

Insulin (First Line)

• Basal-bolus regimen: Long-acting insulin (NPH, detemir, or glargine) + Short-acting insulin (regular, lispro, or aspart) at mealtimes
• OR continuous subcutaneous insulin infusion (CSII/insulin pump) - preferred in T1DM; improves neonatal outcomes and reduces retinopathy progression

• Short-acting: Regular, Lispro (B), Aspart (B)
• Intermediate: NPH
• Long-acting: Detemir (B), Glargine (C - limited data but widely used)

Oral Hypoglycemic Agents

Continuous Glucose Monitoring (CGM)

• Evidence-based intervention for T1DM in pregnancy - improves neonatal outcomes
• Real-time CGM helps detect nocturnal hypoglycemia and postprandial spikes
• Increasingly used in T2DM and GDM with pharmacotherapy

---

9. FETAL SURVEILLANCE

FLOWCHART 3: Antepartum Fetal Surveillance

DIAGNOSED GDM/PGDM
        │
    ┌───┴────────────────────────────┐
    ▼                                ▼
GDM (diet-controlled)          GDM on therapy / PGDM
    │                                │
Serial growth scans            Serial growth scans
(28, 32, 36 weeks)             (every 4-6 weeks from 28 wks)
    │                                │
    └────────────┬────────────────────┘
                 ▼
    ANOMALY SCAN: 18-20 weeks (PGDM)
    FETAL ECHO: 22-24 weeks (PGDM)
                 │
                 ▼
         From 32-34 weeks:
    Non-Stress Test (NST) - weekly
    Biophysical Profile (BPP) if NST non-reactive
    Doppler studies if IUGR suspected
                 │
                 ▼
    Ultrasound for:
    - Estimated Fetal Weight (EFW)
    - Amniotic fluid index (AFI)
    - Polyhydramnios = marker of poor glycemic control
    - LGA = indicator of suboptimal control
                 │
                 ▼
    EFW > 4500g → Consider Elective C/S
    EFW > 4000g in poorly controlled DM → discuss C/S

---

10. INTRAPARTUM AND DELIVERY MANAGEMENT

Timing of Delivery

Mode of Delivery

• Vaginal delivery preferred when possible
• Elective cesarean delivery for EFW ≥4500 g (to minimize shoulder dystocia risk)
• EFW 4000-4500 g: individualized decision based on pelvis, labor progress, history

Intrapartum Glucose Management

• Target blood glucose: 70-126 mg/dL (4-7 mmol/L) during labor
• Glucose-insulin drip (if on insulin): maintain normoglycemia to prevent neonatal hypoglycemia from fetal hyperinsulinism
• Monitor blood glucose every 1-2 hours during labor
• Tight glycemic control at delivery minimizes neonatal hypoglycemia

---

11. NEONATAL MANAGEMENT

---

12. POSTPARTUM MANAGEMENT

GDM Postpartum Follow-up - CRITICAL

DELIVERY
   │
   ▼
DISCONTINUE all insulin/medications for GDM
(insulin requirements drop dramatically after delivery of placenta)
   │
   ▼
4-12 WEEKS POSTPARTUM:
75-g 2-hour OGTT (not HbA1c - inadequate sensitivity)
   │
   ├── Normal → Lifestyle counseling
   │           Rescreen every 1-3 years
   │
   ├── Prediabetes → Intensive lifestyle modification
   │                 Metformin (reduces DM risk 50%)
   │
   └── T2DM → Refer for diabetes management
   │
   ▼
LONG-TERM RISK:
- 7-10x increased risk of T2DM later in life
- 10% risk within 5 years of delivery
- Increased cardiovascular disease risk
- Encourage:
  - Exercise, weight loss
  - Breastfeeding (reduces GDM recurrence)
  - Metformin in high-risk individuals

PGDM Postpartum

• Resume pre-pregnancy insulin regimen (doses may need reduction due to improved sensitivity after delivery)
• Breastfeeding: insulin preferred; metformin/glyburide compatible with breastfeeding in limited data
• Contraception counseling (combined OCP may worsen insulin resistance)
• Screen for postpartum depression (increased in diabetic mothers)

---

13. SPECIAL SITUATIONS

A. GDM Diagnosed Early in Pregnancy

B. GCK-MODY (Monogenic Diabetes)

• Estimated 0.5-6% of GDM may be GCK-MODY
• Heterozygous GCK mutation: mild lifelong fasting hyperglycemia, normal BMI, autosomal dominant FH
• Key: if fetus also carries mutation → IUGR (fetal insulin ↓ → growth ↓)
• If fetus is unaffected → macrosomia (maternal hyperglycemia drives fetal insulin)
• Genetic testing indicated after counseling in suspected cases

C. Bariatric Surgery and Pregnancy

• Avoid conception for 12-18 months post-surgery
• Bariatric surgery reduces GDM risk but increases micronutrient deficiency risk
• Require increased surveillance for iron, B12, folate, calcium, vitamin D deficiencies

D. DKA in Pregnancy - Management Priorities

• Aggressive IV fluid resuscitation (normal saline)
• Insulin infusion (0.1 units/kg/hr)
• Electrolyte replacement (especially potassium)
• Continuous fetal monitoring
• Identify and treat precipitating cause
• DKA resolves as maternal condition improves; emergency delivery usually not indicated unless fetal distress persists after maternal stabilization

---

14. SUMMARY COMPARISON TABLE: GDM vs PGDM

---

15. RECENT EVIDENCE UPDATES (2023-2026)

---

REFERENCES

• Creasy & Resnik's Maternal-Fetal Medicine: Principles and Practice (9th ed.) - Chapter 59: Diabetes in Pregnancy [Primary source]
• Harrison's Principles of Internal Medicine 22nd Ed (2025) - Chapter on Diabetes Mellitus in Pregnancy, pp. 3943-3944
• Tintinalli's Emergency Medicine - Chapter: Diabetes in Pregnancy (pp. 664)
• Goldman-Cecil Medicine International Edition - Chapter: Gestational Diabetes
• IADPSG Consensus Panel. Diabetes Care. 2010;33:676-682
• ADA Standards of Medical Care in Diabetes. Diabetes Care. 2021-2024
• ACOG Practice Bulletin No. 190. Obstet Gynecol. 2018;131:e49-e64
• HAPO Study Cooperative Research Group. N Engl J Med. 2008;358:1991-2002

---

Clinical Pearl: The key distinction for the PG exam is that congenital malformations are a feature of PGDM (hyperglycemia during the first 5-8 weeks of organogenesis), while macrosomia and neonatal hypoglycemia occur in both GDM and PGDM via the Pedersen hyperglycemia-hyperinsulinism hypothesis. The diagnosis of GDM is made after organogenesis, so structural defects are not increased in isolated GDM.

Exam Tip: Insulin is the preferred pharmacological agent for both GDM and PGDM in pregnancy. HbA1c is unreliable for monitoring during pregnancy (false low due to high RBC turnover). Postpartum screening at 4-12 weeks with a 75g OGTT is mandatory for all women with GDM.This is a comprehensive PG-level answer on Diabetes in Pregnancy drawn from Creasy & Resnik's Maternal-Fetal Medicine (9th ed.), Harrison's Principles of Internal Medicine (22nd ed., 2025), Tintinalli's Emergency Medicine, and updated with 2023-2026 PubMed evidence. Here's a summary of what's covered:

---

What's Included

• Two-step method (ACOG standard, USA) - 50g GCT → 100g 3-hr OGTT
• One-step method (IADPSG/WHO) - 75g 2-hr OGTT
• Exact diagnostic thresholds with tables (Carpenter-Coustan vs IADPSG)
• The HAPO study basis and the ongoing controversy